RESUMEN
OBJECTIVE: To assess the endometrial effects of bazedoxifene acetate in healthy postmenopausal women. METHODS: The endometrial effects of bazedoxifene 2.5, 5.0, 10, 20, 30, and 40 mg/d were evaluated in a 2-part, 6-month, double-blind, randomized, active- and placebo-controlled study among a total of 497 healthy postmenopausal women. Conjugated estrogens (0.625 mg)/medroxyprogesterone acetate (2.5 mg) served as the active control. Patients underwent transvaginal ultrasonography to measure double-wall endometrial thickness and endometrial biopsy at baseline and at 6 months of treatment. The incidence of amenorrhea was assessed from self-reported daily diaries. RESULTS: Bazedoxifene treatment at 2.5-20 mg/d resulted in mean changes from baseline in endometrial thickness that were no different than those seen with placebo treatment. Changes in endometrial thickness for the bazedoxifene 30 and 40 mg groups were significantly smaller than for placebo. The change from baseline in endometrial thickness was significantly and inversely related to dose (P < or = .001). None of the endometrial biopsy specimens demonstrated endometrial hyperplasia. Subjects in the 2.5-20 mg bazedoxifene groups experienced amenorrhea rates of 57-74%, comparable with the 59% seen in placebo. Over 90% of subjects treated with bazedoxifene 30 or 40 mg/d were amenorrheic at 6 months. CONCLUSION: Bazedoxifene at dosages up to 40 mg/d was well tolerated and did not stimulate the endometrium. The significant decreases in endometrial thickness and decreased uterine bleeding observed with doses of 30 and 40 mg/d as compared with placebo suggest endometrial antagonism, representing a novel characteristic not previously associated with any selective estrogen receptor modulator.
Asunto(s)
Endometrio/efectos de los fármacos , Indoles/farmacología , Moduladores Selectivos de los Receptores de Estrógeno/farmacología , Adulto , Anciano , Método Doble Ciego , Endometrio/citología , Endometrio/diagnóstico por imagen , Femenino , Humanos , Indoles/administración & dosificación , Menopausia/efectos de los fármacos , Persona de Mediana Edad , Osteoporosis/prevención & control , Posmenopausia , Moduladores Selectivos de los Receptores de Estrógeno/administración & dosificación , UltrasonografíaRESUMEN
Os autores realizaram análise dos níveis de fibrinogênio, comparando mulheres na menacme e na pós-menopausa, com e sem reposiçao estroprogestativa, atendidas nos Setores de Ginecologia Endócrina da Disciplina de Ginecologia da Universidade Federal de Sao Paulo (Escola Paulista de Medicina) e da Faculdade de Medicina do Triângulo Mineiro. Realizaram uma breve revisao do sistema de coagulaçao sangüíneo e açao da terapia de reposiçao estroprogestativa sobre os níveis de fibrinogênio. Observaram que os níveis de fibrinogênio foram semelhantes em mulheres na menacme e na pós-menopausa; de igual modo, os valores na pós-menopausa na vigência de terapêutica de reposiçao hormonal estroprogestativa nao se alteraram.
Asunto(s)
Humanos , Femenino , Adulto , Persona de Mediana Edad , Fibrinógeno/análisis , Ciclo Menstrual , Posmenopausia , Terapia de Reemplazo de Estrógeno , Coagulación Sanguínea , Viscosidad SanguíneaRESUMEN
Os autores relatam vários casos de disgenesia gonadal em duas famílias, com o intuito de mostrar a possibilidade de existência de fator hereditário na sua tiologia. Também tecem comentários sobre algumas características desta síndrome.
Asunto(s)
Humanos , Masculino , Femenino , Disgenesia Gonadal/genéticaRESUMEN
A sindrome dos ovarios policisticos(SOP) e o resultado deuma heterogeneidade de disturbios que, fundamentalmente,elevam a concentracao intra-ovariana de androgenios. Embora a anovulacao, o hirsutismo, a obesidade, e os ovarios com multiplos cistos sejam considerados as manifestacoes classicas dadoenca, ela pode ser encontrada com um espectro variado de achados clinicos, laboratoriais e etiopatogenicos.